Murphey Mark D
Department of Radiologic Pathology, Armed Forces Institute of Pathology, Washington, DC 20306, USA.
Semin Musculoskelet Radiol. 2007 Sep;11(3):201-14. doi: 10.1055/s-2008-1038310.
The working group of the World Health Organization (WHO) for classification of tumors of soft tissue and bone met in 2002. The consensus of this conference led to modifications in the nomenclature primarily for soft tissue neoplasm, leaving osseous tumors largely unaltered. The most significant changes in nomenclature involved the group of fibrous and lipomatous malignancies. This article reviews the modifications of this nomenclature and the justification for these changes. The WHO suggested replacement of the term MALIGNANT FIBROUS HISTIOCYTOMA (MFH) with undifferentiated high-grade pleomorphic sarcoma and combining myxoid and round cell liposarcoma under the umbrella of myxoid liposarcoma. The imaging appearances of the fibrous and lipomatous malignancies is reviewed and emphasized in this article. It is important for radiologists involved in evaluation of these lesions to have an understanding of the current nomenclature. This allows improved uniformity in our discussions with pathologists and orthopedic oncologists in our team approach in the diagnosis and treatment of these patients.
世界卫生组织(WHO)软组织和骨肿瘤分类工作组于2002年召开会议。本次会议的共识主要导致了软组织肿瘤命名法的修改,而骨肿瘤的命名基本未变。命名法中最显著的变化涉及纤维性和脂肪性恶性肿瘤组。本文回顾了该命名法的修改内容及这些变化的依据。WHO建议用未分化高级别多形性肉瘤取代恶性纤维组织细胞瘤(MFH)这一术语,并将黏液样和圆形细胞脂肪肉瘤合并为黏液样脂肪肉瘤。本文对纤维性和脂肪性恶性肿瘤的影像学表现进行了回顾并予以强调。参与这些病变评估的放射科医生了解当前的命名法很重要。这有助于我们在与病理科医生和骨科肿瘤学家团队协作诊断和治疗这些患者的过程中,实现讨论的更好一致性。